Related Experiment Video
Updated: Mar 4, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
An ISO 31000-Based Risk Matrix for Risk Management in Anticancer Drug Prescription, Compounding, and Administration
Alessandro Morabito1, Piera Maiolino2, Stefania D'Auria3
1Thoracic Department, Division of Thoracic Medical Oncology, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Napoli, Italy.
Background:
This study aims to identify and reduce risks that could negatively impact patient safety and organizational aspects related to the different phases of anticancer drug therapy for lung cancer patients in the Day Hospital (DH) care.
Methods:
From April 2023 until February 2024, a team of multi-disciplinary healthcare professionals of the National Cancer Institute of Naples, Italy, used a modified Delphi approach to identify the care process, the main activities and related risk factors. The severity of these harms and the probability of their occurrence were assessed by applying a 5×5 semi-quantitative ISO 31000:2018 (ISO 31000) risk matrix. Multiple improvement actions were identified and adopted by the team to reduce the risks to acceptable levels.
Results:
Nine main activities, 19 correlated potential risks (10 risks for patient safety domain; 53.0%) (9 risks for organizational area; 47.0%) and 19 mitigation measures were identified. The highest risk levels were recognized in the organizational area for: (i) DH Outpatient Visits, due to delays in patients check-in or lab test results or problems with the prescription software; (ii) anticancer drugs administration, for the unavailability of chemotherapy chairs or lack of dedicated nursing staff. Conversely, risk levels for patient safety area were low overall, because several control measures were already in place. Once the mitigation measures were implemented, a new semi-quantitative risk analysis was performed. Risk levels for organizational area changed from a 44.4% to 0.0% in high level, from 44.4% to 67.0% in moderate level, and from 11.2% to 33.0% in minor level. Risk levels for safety areas did not modify for high level (10.0%), but changed from 50.0% to 10.0% in moderate level and increased from 40.0% to 80.0% in minor level.
Conclusion:
ISO 31000 risk management framework applied to lung cancer DH care could improve both organizational and safety objectives in oncology.
Insights
This study reduced risks in lung cancer Day Hospital care by applying ISO 31000 risk management. Implementing mitigation actions significantly lowered organizational risks and improved patient safety outcomes.
Area of Science:
- Oncology
- Healthcare Management
- Patient Safety
Background:
- Lung cancer patients undergoing anticancer drug therapy in Day Hospitals (DH) face potential patient safety and organizational risks.
- Identifying and mitigating these risks is crucial for optimizing care delivery.
Purpose of the Study:
- To identify and reduce risks impacting patient safety and organizational aspects during lung cancer therapy in a Day Hospital setting.
- To implement and assess the effectiveness of risk mitigation strategies.
Main Methods:
- A modified Delphi approach was used by a multidisciplinary team to identify care processes, activities, and risk factors.
- A 5x5 semi-quantitative ISO 31000 risk matrix assessed harm severity and occurrence probability.
- Improvement actions were identified and adopted to reduce risks.
Main Results:
- 19 potential risks were identified, with 10 affecting patient safety and 9 impacting the organization.
- Highest organizational risks included DH outpatient visits and drug administration.
- Post-mitigation, high-level organizational risks decreased from 44.4% to 0.0%, and moderate patient safety risks reduced from 50.0% to 10.0%.
Conclusions:
- The ISO 31000 risk management framework effectively improved both organizational and safety objectives in lung cancer Day Hospital care.
- This systematic approach enhances the overall quality and safety of oncology patient management.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
05:18Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
Published on: October 6, 2023
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Dosing: Geriatric Patients
Dosage Regimen: Individualization
Hazard Ratio
For example, in a clinical trial...
Pharmaceutical Poisoning: Potential Scenarios
Dosage Regimen Designs: Nomograms and Tabulations